Evidence mapPaperPMID 41142413Full record

ReviewMaterials today. Bio2025

Combating Gram-negative infections: The role of antimicrobial peptides and nanotechnology in overcoming antibiotic resistance.

Christian S Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Rafael Miguel Sábio, Hélder A Santos, Fernando Rogério Pavan

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Whole-Genome Sequencing of Multidrug-ResistantInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Review
  10. Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026
    Review
  11. Article
  12. [Fe(phen)ACS omega · 2025
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christian S Carnero CanalesVicerrectorado de Investigación, Universidad Autónoma del Perú (UA), Lima, 150142, Republic of Peru.
Jessica Ingrid Marquez CazorlaSchool of Pharmacy, Biochemistry and Biotechnology, Santa Maria Catholic University (UCSM), Arequipa, 04013, Republic of Peru.
Renzo Marianito Marquez CazorlaSchool of Pharmacy, Biochemistry and Biotechnology, Santa Maria Catholic University (UCSM), Arequipa, 04013, Republic of Peru.
Rafael Miguel SábioTuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University, Araraquara, 14800-903, Brazil.
Hélder A SantosDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Groningen, 9713 AV, the Netherlands.
Fernando Rogério PavanTuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University, Araraquara, 14800-903, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gram-negative bacterial infections represent a critical global health threat due to rising antibiotic resistance, posing substantial clinical and economic burdens. The structural complexity of Gram-negative bacteria-including efflux pumps, enzymatic degradation mechanisms, genetic mutations, and altered membrane permeability, significantly complicates treatment with conventional antibiotics. Antimicrobial peptides (AMPs) offer great antimicrobial activity, rapid bactericidal effects, multiple mechanisms of action, and immune-modulatory properties. However, their clinical application is limited by enzymatic degradation, potential cytotoxicity, and high production costs. To address these limitations, advanced nanotechnology-based platforms, including lipid-based nanoparticles, polymeric nanoparticles, and inorganic nanoparticles, are being explored as AMP delivery vehicles. These nanocarriers enhance peptide stability, bioavailability, targeted delivery, and therapeutic efficacy while reducing systemic toxicity. This review synthesizes recent advancements in AMPs and nanotechnology-based delivery systems, highlighting their combined potential to effectively combat multidrug-resistant Gram-negative pathogens.

Indexed as

Antimicrobial peptidesDrug delivery systemsGram-negative bacteriaNanocarriersNanotechnology

Identifiers

PMID41142413
PMCPMC12546895

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.